- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 5, 2024Jake Holdreith Named to Twin Cities Business Top 100
-
December 4, 2024Robins Kaplan Obtains $10.5 Million Post-Verdict in Landmark Aerosol Dust Remover Abuse Case
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Resolved Decade-Long Patent Suit and Achieved Complete Freedom to Operate for Collegium-Owned BioDelivery Sciences Int’l
March 2023
Aquestive Therapeutics, Inc. v. BioDelivery Sciences Int’l, Inc., Civ. No. 19-505-D (E.D.N.C.); Indivior Inc. v. BioDelivery Sciences Int’l, Inc., Civ. No. 15-350-D (E.D.N.C.)
When Robins Kaplan client Collegium Pharmaceutical, Inc. acquired BioDelivery Sciences Int’l (BDSI) in March of 2022, that acquisition included two patent litigations pending in the Eastern District of North Carolina where BDSI’s products Bunavail® (buprenorphine and naloxone) buccal film and Belbuca® (buprenorphine) buccal film were accused of infringing Aquestive Therapeutic’s U.S. Patent No. 8,765,167. The parties had been litigating for nearly a decade in federal district courts and in multiple proceedings before the Patent Trial and Appeal Board.
Upon Robins Kaplan's appearance as substitute counsel, BDSI was on the wrong end of a motion to compel seeking extensive document discovery, and Aquestive and its counsel were seeking monetary and non-monetary sanctions against BDSI and its former counsel. The first mission was to right the ship. The Robins Kaplan team collected, reviewed, and produced relevant documents and responded to a barrage of discovery demands in a timely manner and before the Court-ordered deadline. The team also got up to speed on the cases’ history and began crafting defenses and began affirmatively seeking discovery from Aquestive in support of those arguments. Finally, the team crystallized non-infringement defenses, updated contentions, and fought off Aquestive’s motion for sanctions and its fee application.
In its order denying non-monetary sanctions, the Court noted, “The hearing reassured the court that discovery has gotten back on track after BDSI changed counsel in this case….” After litigating for about eight months, the case settled and Collegium and BDSI were delighted to achieve complete freedom—past, present, and future—to operate for a one-time payment of $8.5 million.
When Robins Kaplan client Collegium Pharmaceutical, Inc. acquired BioDelivery Sciences Int’l (BDSI) in March of 2022, that acquisition included two patent litigations pending in the Eastern District of North Carolina where BDSI’s products Bunavail® (buprenorphine and naloxone) buccal film and Belbuca® (buprenorphine) buccal film were accused of infringing Aquestive Therapeutic’s U.S. Patent No. 8,765,167. The parties had been litigating for nearly a decade in federal district courts and in multiple proceedings before the Patent Trial and Appeal Board.
Upon Robins Kaplan's appearance as substitute counsel, BDSI was on the wrong end of a motion to compel seeking extensive document discovery, and Aquestive and its counsel were seeking monetary and non-monetary sanctions against BDSI and its former counsel. The first mission was to right the ship. The Robins Kaplan team collected, reviewed, and produced relevant documents and responded to a barrage of discovery demands in a timely manner and before the Court-ordered deadline. The team also got up to speed on the cases’ history and began crafting defenses and began affirmatively seeking discovery from Aquestive in support of those arguments. Finally, the team crystallized non-infringement defenses, updated contentions, and fought off Aquestive’s motion for sanctions and its fee application.
In its order denying non-monetary sanctions, the Court noted, “The hearing reassured the court that discovery has gotten back on track after BDSI changed counsel in this case….” After litigating for about eight months, the case settled and Collegium and BDSI were delighted to achieve complete freedom—past, present, and future—to operate for a one-time payment of $8.5 million.
Past results are reported to provide the reader with an indication of the type of litigation we practice. They do not and should not be construed to create an expectation of result in any other case, as all cases are dependent upon their own unique fact situation and applicable law.
Related Professionals
Similar Results
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.